Drug,Chemical Structure,Adverse Effect / Toxicity,Species,Dose,Dose Type,Route,Source,Source Link,Year,no_stereoisomer
Ambrisentan,COC([C@H](OC1=NC(C)=CC(C)=N1)C(O)=O)(C1=CC=CC=C1)C1=CC=CC=C1,Autoimmune hepatitis,Human,-1.0,Repeated,Oral,"EMA approval document: ANNEX I, page:10 PDF 491k",https://www.pharmapendium.com/browse/ema/Ambrisentan/402a01379b9c3d87e6cbd5166068660b?reference=10,2019.0,COC([CH](OC1=NC(C)=CC(C)=N1)C(O)=O)(C1=CC=CC=C1)C1=CC=CC=C1
Bosentan,COC1=CC=CC=C1OC1=C(OCCO)N=C(N=C1NS(=O)(=O)C1=CC=C(C=C1)C(C)(C)C)C1=NC=CC=N1,Autoimmune hepatitis,Human,-1.380211241711606,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 209279/S-000 Part 04, page:21 PDF 7924k",https://www.pharmapendium.com/browse/fda/Bosentan/bb18b2cae9f370aad27a6398d1bfc58f?reference=21,2017.0,COC1=CC=CC=C1OC1=C(OCCO)N=C(N=C1NS(=O)(=O)C1=CC=C(C=C1)C(C)(C)C)C1=NC=CC=N1
Cetirizine Hydrochloride,OC(=O)COCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1,Autoimmune hepatitis,Human,-1.0,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 022155/S-000 Part 01, page:63 PDF 7190k",https://www.pharmapendium.com/browse/fda/Cetirizine Hydrochloride/5477eee343e2d9bd7ae6807c4260c83f?reference=63,2007.0,OC(=O)COCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1
Liraglutide,CCCCCCCCCCCCCCCC(=O)N[C@@H](CCC(=O)NCCCC[C@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CN=CN1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)C(O)=O,Autoimmune hepatitis,Human,-0.47712125471966244,Repeated,Subcutaneous,"FDA approval package document: Medical/Clinical Review 206321/S-000 Part 16, page:12 PDF 2777k",https://www.pharmapendium.com/browse/fda/Liraglutide/94e64c58d89e46604d426d899ad49e42?reference=12,2014.0,CCCCCCCCCCCCCCCC(=O)N[CH](CCC(=O)NCCCC[CH](NC(=O)[CH](C)NC(=O)[CH](C)NC(=O)[CH](CCC(N)=O)NC(=O)CNC(=O)[CH](CCC(O)=O)NC(=O)[CH](CC(C)C)NC(=O)[CH](CC1=CC=C(O)C=C1)NC(=O)[CH](CO)NC(=O)[CH](CO)NC(=O)[CH](NC(=O)[CH](CC(O)=O)NC(=O)[CH](CO)NC(=O)[CH](NC(=O)[CH](CC1=CC=CC=C1)NC(=O)[CH](NC(=O)CNC(=O)[CH](CCC(O)=O)NC(=O)[CH](C)NC(=O)[CH](N)CC1=CN=CN1)[CH](C)O)[CH](C)O)C(C)C)C(=O)N[CH](CCC(O)=O)C(=O)N[CH](CC1=CC=CC=C1)C(=O)N[CH]([CH](C)CC)C(=O)N[CH](C)C(=O)N[CH](CC1=CNC2=C1C=CC=C2)C(=O)N[CH](CC(C)C)C(=O)N[CH](C(C)C)C(=O)N[CH](CCCNC(N)=N)C(=O)NCC(=O)N[CH](CCCNC(N)=N)C(=O)NCC(O)=O)C(O)=O
Minocycline Hydrochloride,[H][C@@]12CC3=C(C(O)=CC=C3N(C)C)C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])C2,Autoimmune hepatitis,Human,-0.0,Repeated,Oral,"FDA approval package document: Label 201922/S-000, page:14 PDF 1217k",https://www.pharmapendium.com/browse/fda/Minocycline Hydrochloride/8d12f178dbe9bf9d84fa3e5c1cd19687?reference=14,2012.0,[H][C]12CC3=C(C(O)=CC=C3N(C)C)C(=O)C1=C(O)[C]1(O)C(=O)C(C(N)=O)=C(O)[CH](N(C)C)[C]1([H])C2
Mirabegron,NC1=NC(CC(=O)NC2=CC=C(CCNC[C@H](O)C3=CC=CC=C3)C=C2)=CS1,Autoimmune hepatitis,Human,-2.0,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 202611/S-000 Part 11, page:20 PDF 438k",https://www.pharmapendium.com/browse/fda/Mirabegron/9a02d579d37a7b9538ee3d6dc7897cf5?reference=20,2012.0,NC1=NC(CC(=O)NC2=CC=C(CCNC[CH](O)C3=CC=CC=C3)C=C2)=CS1
Mitotane,ClC(Cl)C(C1=CC=C(Cl)C=C1)C1=C(Cl)C=CC=C1,Autoimmune hepatitis,Human,-3.7781512503836434,Repeated,Oral,"EMA approval document: ANNEX I, page:7 PDF 425k",https://www.pharmapendium.com/browse/ema/Mitotane/a7a1adb13e3e762744b74fe4e101a823?reference=7,2020.0,ClC(Cl)C(C1=CC=C(Cl)C=C1)C1=C(Cl)C=CC=C1
Rosuvastatin Calcium,CC(C)C1=C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)C(=NC(=N1)N(C)S(C)(=O)=O)C1=CC=C(F)C=C1,Autoimmune hepatitis,Human,-1.3010299956639813,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 021366/S-016, page:98 PDF 14654k",https://www.pharmapendium.com/browse/fda/Rosuvastatin Calcium/c9e97140cc171cec00fa8144dbec96fd?reference=98,2010.0,CC(C)C1=C(\C=C\[CH](O)C[CH](O)CC([O-])=O)C(=NC(=N1)N(C)S(C)(=O)=O)C1=CC=C(F)C=C1
Ulipristal Acetate,[H][C@@]12CCC3=CC(=O)CCC3=C1[C@H](C[C@@]1(C)[C@@]2([H])CC[C@]1(OC(C)=O)C(C)=O)C1=CC=C(C=C1)N(C)C,Autoimmune hepatitis,Human,-0.6989700043360189,Repeated,Oral,"EMA approval document: Assessment Report EMA/70192/2018; EMEA/H/A-31/1496, page:5 PDF 374k",https://www.pharmapendium.com/browse/ema/Ulipristal Acetate/c129333ea657fa9e9bb2fdc3911b5801?reference=5,2020.0,[H][C]12CCC3=CC(=O)CCC3=C1[CH](C[C]1(C)[C]2([H])CC[C]1(OC(C)=O)C(C)=O)C1=CC=C(C=C1)N(C)C
